Skip to main content

Branded

  • Protein Sciences promotes Flublok influenza shot through social media

    MERIDEN, Conn. - Protein Sciences is looking to drum up some brand recognition behind its flu shot with a new social media campaign - #ShowMeTheVial - featuring Flublok influenza vaccine.  

    To promote awareness and healthy living, raise money for organizations supporting patients and encourage individuals to ask for Flublok, Protein Sciences will donate money to charity each time someone "shows them the Flublok vial."

    In addition, participants will be entered to win a Fit & Healthy prize package that includes a new Fitbit Blaze.

  • Mallinckrodt donates drug deactivation pouches in 7 states
    CHESTERFIELD, U.K. — Mallinckrodt Pharmaceuticals announced Thursday that it would be making it easier for people in the Midwest and in central Appalachia to dispose of their leftover prescription medications. The company will be making 160,000 drug deactivation pouches to families at nearly 800 Walmart stores in Indiana, Kentucky, Ohio, Pennsylvania, South Carolina, Tennessee and West Virginia.
     

  • Endo CFO to depart
    DUBLIN —Endon international announced Friday that its EVP and CFO Suketu Upadhyay would be leaving the company, effective Nov. 22, to assume a senior-level finance position at a global biopharmaceutical company. Endo SVP global finance operations Blaise Coleman will serve as interim CFO, and Endo said it would begin a search for a permanent replacement for Upadhyay. 
     

  • Gilead honors Camber parent company Hetero Drugs
    PISCATAWAY, N.J. — Camber Pharmaceuticals announced Wednesday that its parent company, Hetero Drugs, has been recognized by Gilead Sciences for its work providing access to hepatitis C drugs for patients worldwide. Hetero markets sofosbuvir  as Sofovir and ledipasvir-sofosbuvir as Ledifos in India and will eventually reach some 91 countries. The two drugs are better known in the United States and as Sovaldi and Harvoni. 
     
    In India, an estimated 12 million to 18 million patients are infected with hepatitis C. 

  • Naloxone access, community efforts work to curb opioid abuse

    Drug overdoses have become the leading cause of accidental death in the United States, with 47,055 people dying in 2014 as a result of lethal drug overdoses — 18,893 of which were related to prescription pain relievers. The epidemic has drawn the attention of everyone from President Barack Obama to local first responders, all of whom have pointed to the drug naloxone as one of the critical first lines of defense in saving the lives of thousands from accidental overdose. Naloxone can reverse the effects of an overdose, but until recently it could only be accessed by prescription.

  • Napo Pharmaceuticals launches Mytesi
    NEW YORK — Napo Pharmaceuticals on Thursday announced the launch of its Mytesi (crofelemer), approved by the Food and Drug Administration as a treatment for non-infectious diarrhea in patients with HIV/AIDS on retroviral therapy. The active ingredient is a plant-based drug extracted from the red bark sap of a tree in the Amazon, for which Napo has set up a sustainable harvesting program. 
     

  • HDA to host annual Traceability Seminar

    ARLINGTON, Va. — The Healthcare Distribution Alliance (HDA, formerly HDMA) will host its annual Traceability Seminar Nov. 9–11, 2016, at the Renaissance Washington, DC Downtown Hotel. The seminar will host supply chain leaders — including distributors, manufacturers, pharmacists and third-party logistics providers — as well as federal/state regulators to discuss upcoming milestones and lessons learned as they continue to implement the Drug Supply Chain Security Act.


  • Merck signs value-based contract with Aetna for Januvia, Janumet
    HARTFORD, Conn. — Merck and Aetna have entered into a value-based agreement for Merck’s Type  diabetes medications Januvia (sitagliptin) and Janumet (sitagliptin plus metformin. The contract will see Merck’s rebates for the drugs based partly on their ability to help Aetna’s commercial members with Type 2 diabetes achieve or maintain treatment goals. 
     
X
This ad will auto-close in 10 seconds